Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis : a population-based study

Hallmer, Fredrik ; Bjarnadottir, Olof LU ; Götrick, Bengt ; Malmström, Per LU and Andersson, Gunilla (2020) In Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 130(3). p.252-257
Abstract

Objective: The aim of this study was to prospectively determine the incidence of medication-related osteonecrosis of the jaw (MRONJ) and define risk factors in patients with metastatic breast cancer treated with zoledronic acid and/or denosumab. Study Design: In a prospective cohort study performed in Region Skåne, Sweden, from January 1, 2012, until December 31, 2015, all patients with breast cancer who had radiographic evidence of bone metastases and were treated with zoledronic acid or denosumab were included and followed up until May 31, 2018. Results: Of the 242 patients, MRONJ developed in 16 (6.6%) during the 77 months of study. The incidence of MRONJ in patients treated with zoledronic acid was 4.1%, and in patients treated with... (More)

Objective: The aim of this study was to prospectively determine the incidence of medication-related osteonecrosis of the jaw (MRONJ) and define risk factors in patients with metastatic breast cancer treated with zoledronic acid and/or denosumab. Study Design: In a prospective cohort study performed in Region Skåne, Sweden, from January 1, 2012, until December 31, 2015, all patients with breast cancer who had radiographic evidence of bone metastases and were treated with zoledronic acid or denosumab were included and followed up until May 31, 2018. Results: Of the 242 patients, MRONJ developed in 16 (6.6%) during the 77 months of study. The incidence of MRONJ in patients treated with zoledronic acid was 4.1%, and in patients treated with denosumab, it was 13.6%. The risk of MRONJ was higher in patients on denosumab than in those treated with zoledronic acid (P =.011). Corticosteroid use was associated with a decreased risk of MRONJ (P =.008), and diabetes was associated with an increased risk of MRONJ (P =.02). Conclusions: The incidence of MRONJ is 13.6% (>3 times higher) in denosumab-treated patients with breast cancer compared with that in patients treated with zoledronic acid (4.1%). Corticosteroid use decreased the risk of MRONJ.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
volume
130
issue
3
pages
6 pages
publisher
Elsevier
external identifiers
  • scopus:85086574678
  • pmid:32536575
ISSN
2212-4403
DOI
10.1016/j.oooo.2020.04.808
language
English
LU publication?
yes
id
34f2f7bb-d47c-4aad-a042-c2f46c50bb7f
date added to LUP
2021-01-14 10:55:57
date last changed
2024-03-05 18:54:21
@article{34f2f7bb-d47c-4aad-a042-c2f46c50bb7f,
  abstract     = {{<p>Objective: The aim of this study was to prospectively determine the incidence of medication-related osteonecrosis of the jaw (MRONJ) and define risk factors in patients with metastatic breast cancer treated with zoledronic acid and/or denosumab. Study Design: In a prospective cohort study performed in Region Skåne, Sweden, from January 1, 2012, until December 31, 2015, all patients with breast cancer who had radiographic evidence of bone metastases and were treated with zoledronic acid or denosumab were included and followed up until May 31, 2018. Results: Of the 242 patients, MRONJ developed in 16 (6.6%) during the 77 months of study. The incidence of MRONJ in patients treated with zoledronic acid was 4.1%, and in patients treated with denosumab, it was 13.6%. The risk of MRONJ was higher in patients on denosumab than in those treated with zoledronic acid (P =.011). Corticosteroid use was associated with a decreased risk of MRONJ (P =.008), and diabetes was associated with an increased risk of MRONJ (P =.02). Conclusions: The incidence of MRONJ is 13.6% (&gt;3 times higher) in denosumab-treated patients with breast cancer compared with that in patients treated with zoledronic acid (4.1%). Corticosteroid use decreased the risk of MRONJ.</p>}},
  author       = {{Hallmer, Fredrik and Bjarnadottir, Olof and Götrick, Bengt and Malmström, Per and Andersson, Gunilla}},
  issn         = {{2212-4403}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{252--257}},
  publisher    = {{Elsevier}},
  series       = {{Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology}},
  title        = {{Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis : a population-based study}},
  url          = {{http://dx.doi.org/10.1016/j.oooo.2020.04.808}},
  doi          = {{10.1016/j.oooo.2020.04.808}},
  volume       = {{130}},
  year         = {{2020}},
}